Real-world clinical outcomes in patients with relapsed and refractory multiple myeloma receiving VTD-PACE treatment in the era of monoclonal antibodies
T Kikuchi, N Tsukada, K Kunisada, M Nomura-Yogo… - Annals of …, 2023 - Springer
Abstract Bortezomib (Velcade), thalidomide, dexamethasone, platinum (cisplatin),
adriamycin (doxorubicin), cyclophosphamide, and etoposide (VTD-PACE) are commonly …
adriamycin (doxorubicin), cyclophosphamide, and etoposide (VTD-PACE) are commonly …
Anti-BCMA and GPRC5D bispecific antibodies in relapsed/refractory primary plasma cell leukemia: a case report
C Bernardi, Y Beauverd, TA Tran, M Maulini… - Frontiers in …, 2024 - frontiersin.org
Plasma cell leukemia (PCL) is an aggressive and high-risk variant of multiple myeloma (MM)
with a very poor prognosis. Given its rarity and aggressiveness, there is a lack of clinical …
with a very poor prognosis. Given its rarity and aggressiveness, there is a lack of clinical …
Intensive salvage chemotherapy with VDTPACE or mCBAD followed by hematopoietic stem‐cell support for refractory/relapsed multiple myeloma
CP Marques, D Ovigli, MN Kerbauy… - European Journal of …, 2024 - Wiley Online Library
Introduction Triple‐and quad‐refractory multiple myeloma patients usually have an
aggressive course and a poor prognosis. Available therapeutic options are scarce. Methods …
aggressive course and a poor prognosis. Available therapeutic options are scarce. Methods …
Outcomes of Salvage VDT-PACE-like Regimens in Relapsed-Refractory Multiple Myeloma: 10-Year Experience of a Large Academic Institution
Methods: We retrospectively analyzed medical records of patients with RRMM who were
treated with VPRs at our institution between 1/1/2013 and 6/1/2023. Responses including …
treated with VPRs at our institution between 1/1/2013 and 6/1/2023. Responses including …